دورية أكاديمية
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
| العنوان: | A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma |
|---|---|
| المؤلفون: | Noel, Robin, Zemmour, Christophe, Montes de Oca, Catalina, Belmecheri, Nawel, Aurran-Schleinitz, Thérèse, Coso, Diane, Lopez Almeida, Leonor, Mescam, Lénaïg, Vey, Norbert, Bladé, Jean, Sébastien, Slama, Borhane, Bouabdallah, Reda, Schiano de Colella, Jean-Marc |
| المساهمون: | Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Unité de Biostatistique et de Méthodologie Institut Paoli-Calmettes, Marseille (Département de la Recherche Clinique et de l’Innovation), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hopital d'instruction des armées Sainte-Anne Toulon (HIA), Centre Hospitalier Henri Duffaut (Avignon) |
| المصدر: | ISSN: 1024-5332. |
| بيانات النشر: | HAL CCSD Maney Publishing |
| سنة النشر: | 2023 |
| المجموعة: | Aix-Marseille Université: HAL |
| مصطلحات موضوعية: | Relapsed/refractory diffuse large B cell lymphoma, rituximab and lenalidomide, clinical trial, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie |
| الوصف: | International audience ; Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40-86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1-12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7-2.9]) and median overall survival was 9.3 months (95% CI, [5.1-Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37133334; inserm-04539614; https://inserm.hal.science/inserm-04539614Test; https://inserm.hal.science/inserm-04539614/documentTest; https://inserm.hal.science/inserm-04539614/file/Hematology2023_RobinNoel.pdfTest; PUBMED: 37133334 |
| DOI: | 10.1080/16078454.2023.2207948 |
| الإتاحة: | https://doi.org/10.1080/16078454.2023.2207948Test https://inserm.hal.science/inserm-04539614Test https://inserm.hal.science/inserm-04539614/documentTest https://inserm.hal.science/inserm-04539614/file/Hematology2023_RobinNoel.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.59ED1613 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1080/16078454.2023.2207948 |
|---|